CancerNCT03530826
A Crowd Sourcing Platform for Patients With Cancer
An observational study of Cancer, run by All4Cure at 1 site in United States.
Trial summary
All4Cure aims to accelerate learning about cancer by sharing medical information and research results from cancer patients with fellow cancer patients, oncologists, and scientists on the All4Cure website with the hope that together patients, clinicians and researchers can cure cancer faster. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- How many people
- 5,000 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Apr 2018to 31 Jan 2028
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult cancer patients
Who may be able to join
- Have been diagnosed with cancer.
- Be under the care of a physician.
- Be 18 years of age or older.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
All4Cure
Seattle, Washington, 98136
Carl A Blau, MD, 206-412-1787, tony@all4cure.com
Kimberly A Burton, PhD, 2069482711, kaburton@all4cure.com
About this study
All4Cure aims to accelerate learning about cancer by sharing medical information and research results from cancer patients with fellow cancer patients, oncologists, and scientists on the All4Cure website with the hope that together patients, clinicians and researchers can cure cancer faster.
Read the detailed description
The core hypothesis tested by this study is that engaging researchers, clinicians and patients in an online knowledge sharing platform will enable patients to better understand cancer, better inform treatment decisions made by oncologists and accelerate cancer research. Leftover samples from patients with cancer (blood, bodily fluids and/or tissues collected for clinical purposes) will be obtained and sent for various types of analyses and results will be shared on the All4Cure website.
- Conditions
- Cancer
- Being tested
- No intervention
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
No Intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in tumor tissue molecular profiles
Profiles of pre- and post-treatment tumor tissue will be compared.
Measured: 6 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 May 2018
- Study start26 Apr 2018
- Primary completion31 Jan 2028 (estimated)
- Study completion31 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- All4Cure
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Principal investigator, Carl Anthony Blau, MD, All4Cure
- Investigators
- Carl A Blau, MD, Principal investigator, All4Cure
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03530826
- Sponsor's protocol ID
- All4Cure01
- Status last verified
- Jul 2024
- First submitted
- 7 May 2018
- Last updated
- 30 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: nonidentifiable clinical and research data may be shared with other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Crowd Sourcing Platform for Patients With Cancer
- ClinicalTrials.gov ID
- NCT03530826
- Acronym / sponsor ID
- All4Cure01
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- All4CureIndustry (pharma, biotech, devices)
- Study start
- 26 Apr 2018 (actual)
- Primary completion
- 31 Jan 2028 (estimated)
- Study completion
- 31 Jan 2028 (estimated)
- First posted
- 21 May 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
All4Cure aims to accelerate learning about cancer by sharing medical information and research results from cancer patients with fellow cancer patients, oncologists, and scientists on the All4Cure website with the hope that together patients, clinicians and researchers can cure cancer faster.
Detailed description
The core hypothesis tested by this study is that engaging researchers, clinicians and patients in an online knowledge sharing platform will enable patients to better understand cancer, better inform treatment decisions made by oncologists and accelerate cancer research. Leftover samples from patients with cancer (blood, bodily fluids and/or tissues collected for clinical purposes) will be obtained and sent for various types of analyses and results will be shared on the All4Cure website.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult cancer patients
Key inclusion criteria (3 listed)
- Have been diagnosed with cancer.
- Be under the care of a physician.
- Be 18 years of age or older.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionNo Intervention | Other | – |
Primary outcome
Change in tumor tissue molecular profiles
Time frame: 6 years
Profiles of pre- and post-treatment tumor tissue will be compared.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2024.
- Individual participant dataSharing planned: Undecided. nonidentifiable clinical and research data may be shared with other researchers.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Carl A Blau, MD principal investigator
All4Cure
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by All4Cure at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Carl A Blau, MD (2064121787, tony@all4cure.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in tumor tissue molecular profiles (time frame: 6 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2024.